进展期胃癌新辅助化疗的研究进展

目的总结进展期胃癌新辅助化疗的研究进展。方法采用文献复习的方法,对有关进展期胃癌新辅助化疗研究进展的文献进行综述。结果进展期胃癌的新辅助化疗可显著提高R0切除率,提高远期生存率,降低死亡风险。对于无远处转移的局部进展期胃癌的新辅助化疗时间一般为6~9周,然后根据疗效评价结果决定是否进行手术治疗;进一步深入的临床研究及化疗敏感程度检测方法的改进有助于新辅助化疗标准的统一。结论进展期胃癌新辅助化疗的疗效已比较明确,但其在适应证、化疗方案、用药时限、疗效评价指标等方面尚无明确的统一标准,仍需要多中心、大型的临床试验进行深入的研究。

Research Progress of Neoadjuvant Chemotherapy in Advanced Gastric Cancer

Objective To summarize the research progress of neoadjuvant chemotherapy in advanced gastric cancer. Method The literatures about the research progress of neoadjuvant chemotherapy in the advanced gastric cancer were reviewed. Results The neoadjuvant chemotherapy in the advanced gastric cancer could significantly improve the R0 resection rate, improve the long-term survival rate, and reduce the risk of death. The course of neoadjuvant chemotherapy for locally advanced gastric cancer without distant metastasis generally was 6-9 weeks, and then according to the results of the curative effect evaluation to decide whether to undergo surgery treatment. Further the clinical research and improvement of chemotherapy sensitivity detection method were helpful to the unity of the standard of neoadjuvant chemotherapy. Conclusions The curative effect of neoadjuvant chemotherapy in advanced gastric cancer is clear. But there is no uniform standard on such as indications, chemotherapy regimens, medication time, and curative effect evaluation index, and so on. It is still needed the further research of multicenter and large clinical trials.